 MediciNova NASDAQ:MNOVs stock had its buy rating reiterated by equities researchers at B. Riley in a research report issued to clients and investors on Monday, TipRanks reports. They currently have a 11.00 price target on the biopharmaceutical companys stock. B. Rileys price target points to a potential upside of 73.50 from the stocks current price. ... 